Source-grounded facts extracted from MANNKIND CORP's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MANNKIND CORP shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-05-20 meeting.
“Our stockholders ratified the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.”
MANNKIND CORP shareholders approved Advisory approval of named executive officer compensation at the 2026-05-20 meeting.
“Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 7, 2026.”
MANNKIND CORP shareholders approved Election of nine directors at the 2026-05-20 meeting.
“Our stockholders elected each of the nine individuals nominated by our Board of Directors to serve as directors until the next annual meeting of stockholders.”
MANNKIND CORP reported the first quarter of 2026 results: revenue $90,171.
“386 3 % Furoscix 15,493 — 15,493 N/A V-Go 3,141 4,086 (945 ) (23 %) Collaborations and services 23,515 29,376 (5,861 ) (20 %) Royalties 32,749 30,005 2,744 9 % Total revenues $ 90,171 $ 78,354 $ 11,817 15 % Total revenues for the first quarter of 2026 increased compared to the same period in the prior year due to higher revenue from royalties and commercial”
MANNKIND CORP incurred credit facility of $250.0 million with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
“On October 7, 2025, the Company borrowed $250.0 million in delayed draw term loans to fund the Acquisition Price and the scPharma Debt Extinguishment.”
MANNKIND CORP amended credit facility of additional $175.0 million incremental delayed draw term loan with Blackstone Alternative Credit Advisors LP (as Blackstone Representative) at one, three or six month term SOFR (at the Company’s election), subject to a 2% f maturing August 6, 2030.
“Pursuant to the Credit Agreement Amendment, among other things, the Lenders agreed to provide an additional $175.0 million incremental delayed draw term loan solely to finance a portion of the fees, premiums, expenses and other transaction costs incurred in connection with the transactions contemplated by the Merger Agreement”
MANNKIND CORP completed an acquisition involving scPharmaceuticals Inc. for approximately $296.5 million (closed 2025-10-07).
“Share outstanding immediately prior to the Effective Time. The aggregate cash paid by the Company and Purchaser in the Offer and the Merger at the Closing Date was approximately $296.5 million (the “ Acquisition Price ”), which was funded by the Company from its available cash on hand and net proceeds from borrowings under its Credit Agreement (as defined below). As”
Burkhard Blank changed role as Chief Medical Officer and Executive Vice President, Research & Development at MANNKIND CORP.
“On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.”
Lauren Sabella departed as Executive Vice President, Operations at MANNKIND CORP.
“On January 2, 2025, Lauren Sabella notified us of her intention to retire from MannKind Corporation (the “Company”), effective July 18, 2025”
Lauren Sabella was appointed as Executive Vice President, Operations at MANNKIND CORP.
“the board of directors of the Company appointed Ms. Sabella as Executive Vice President, Operations, effective January 6, 2025.”
Steven B. Binder departed as Executive Vice President, Special Projects at MANNKIND CORP.
“His employment will end concurrently with his appointment to the Board on the Effective Date.”
Steven B. Binder was appointed as Director at MANNKIND CORP.
“On August 13, 2024, the Board approved the appointment of Steven B. Binder to the Board, effective on the Effective Date.”
Kent Kresa retired as Director at MANNKIND CORP.
“On August 13, 2024, Kent Kresa notified us of his decision to retire from our Board of Directors (the “Board”), effective September 30, 2024 (the “Effective Date”).”
MANNKIND CORP shareholders approved Ratification of selection of Deloitte & Touche LLP as independent registered public accounting firm at the 2024-05-15 meeting.
“Our stockholders ratified the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. The tabulation of votes on this matter was as follows: shares voted for: 191,751,989; shares voted against: 3,751,421; shares abstaining: 1,962,739; and broker non-votes: 0.”
MANNKIND CORP shareholders approved Advisory vote on compensation of named executive officers at the 2024-05-15 meeting.
“Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on April 5, 2024. The tabulation of votes on this matter was as follows: shares voted for: 112,281,517; shares voted against: 11,612,528; shares abstaining: 1,260,654; and broker non-votes: 72,311,450.”
MANNKIND CORP shareholders approved Election of Directors at the 2024-05-15 meeting.
“Our stockholders elected each of the nine individuals nominated by our Board of Directors to serve as directors until the next annual meeting of stockholders. The tabulation of votes in the election was as follows: Nominee Shares Voted For Shares Withheld Broker Non-Votes James S. Shannon 118,794,804 6,359,895 72,311,450 Michael E. Castagna 118,668,999 6,485,700 72,311,450 Ronald J. Consiglio 118,527,948 6,626,751 72,311,450 Michael A. Friedman 118,905,411 6,249,288 72,311,450 Jennifer Grancio 119,237,197 5,917,502 72,311,450 Anthony Hooper 119,772,986 5,381,713 72,311,450 Sabrina Kay 120,046,813 5,107,886 72,311,450 Kent Kresa 119,378,456 5,776,243 72,311,450 Christine Mundkur 119,698,139 5,456,560 72,311,450”
MANNKIND CORP reported the quarter ended March 31, 2024 results: revenue Total revenues of $66M, net income Net income of $11M.
“CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 • 1Q 2024 Net income of $11M; Non-GAAP net income of $15M • $304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid”
Christopher Prentiss was appointed as Chief Financial Officer at MANNKIND CORP.
“On March 25, 2024, the Company’s board of directors appointed Christopher Prentiss as the Company’s Chief Financial Officer and principal accounting officer, effective on April 22, 2024, succeeding Mr. Binder in these capacities.”
Steven B. Binder retired as Chief Financial Officer at MANNKIND CORP.
“Effective April 22, 2024 (the “Effective Date”), Steven B. Binder is retiring as the Chief Financial Officer and principal accounting officer of MannKind Corporation (the “Company”).”
MANNKIND CORP reported the quarter and full year ended December 31, 2023 results: revenue Total revenues of $199M, net income 4Q 2023 Net income of $1M.
“REPORTS 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 2023 Total revenues of $199M; +99% vs. 2022 • 4Q 2023 Total revenues of $58M; +62% vs. 2022 • 4Q 2023 Net income of $1M; Non-GAAP net income of $7M • $302M of cash and cash equivalents and investments at”
MANNKIND CORP entered into Purchase Agreement with Sagard Healthcare Funding Partners Borrower 2 SPE, LP valued at $150 million (effective 2023-12-27).
“On December 27, 2023, MannKind Corporation (the “Company”) entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Sagard Healthcare Funding Partners Borrower 2 SPE, LP (“Sagard”) for the sale to Sagard of a 1% royalty on global net sales of Tyvaso DPI ® (treprostinil) inhalation powder (“Tyvaso DPI”) occurring on and after October 1, 2023 through December 31, 2042 under the Company’s License and Collaboration Agreement dated as of September 3, 2018, as amended (the “License Agreement”), with United Therapeutics Corporation.”
MANNKIND CORP amended Seventh Amendment to Supply Agreement with Amphastar Pharmaceuticals, Inc. valued at €2.9 million annual purchase commitment for 2024; amended purchase commitments through 2035 (effective 2023-12-22).
“On December 22, 2023, MannKind Corporation (the “Company”) entered into a Seventh Amendment to Supply Agreement (the “Seventh Amendment”) with Amphastar Pharmaceuticals, Inc. pursuant to which the parties amended the Supply Agreement, dated July 31, 2014, as amended (the “Supply Agreement”).”
MANNKIND CORP reported quarter ended September 30, 2023 results: revenue Total revenues of $51M, net income Net income of $2M.
“--- EX-99.1 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 • 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 • 3Q 2023 Net income of $2M; Non-GAAP net income of $4M • 3Q 2023 Tyvaso DPI royalties of $20M;”
MANNKIND CORP reported quarter ended June 30, 2023 results: revenue $48,611.
“27 % Net revenue – V-Go 4,818 2,073 $ 2,745 * Revenue – collaborations and services 11,211 5,868 $ 5,343 91 % Royalties – collaborations 19,055 304 $ 18,751 * Total revenues $ 48,611 $ 18,894 $ 29,717 157 % ________________________ * Not meaningful Afrezza net revenue for the second quarter of 2023 increased $2.9 million, or 27%, compared to the same period in”
MANNKIND CORP shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-25 meeting.
“Our stockholders ratified the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.”
MANNKIND CORP shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation (every 1, 2, or 3 years) at the 2023-05-25 meeting.
“Our stockholders indicated, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.”
MANNKIND CORP shareholders approved Advisory vote on the compensation of named executive officers at the 2023-05-25 meeting.
“Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.”
MANNKIND CORP shareholders approved Approval of amendment to the MannKind Corporation 2004 Employee Stock Purchase Plan to increase shares authorized by 3,000,000 shares at the 2023-05-25 meeting.
“Our stockholders approved the ESPP Amendment.”
MANNKIND CORP shareholders approved Approval of amendment to the MannKind Corporation 2018 Equity Incentive Plan to increase shares authorized by 25,000,000 shares at the 2023-05-25 meeting.
“Our stockholders approved the 2018 Plan Amendment.”
MANNKIND CORP shareholders approved Authorization to adjourn the Annual Meeting to solicit additional proxies for the Charter Amendment at the 2023-05-25 meeting.
“Our stockholders authorized an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of the Charter Amendment.”
MANNKIND CORP shareholders approved Amendment to Amended and Restated Certificate of Incorporation to increase authorized common stock from 400,000,000 to 800,000,000 shares at the 2023-05-25 meeting.
“Our stockholders approved an amendment to our Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 400,000,000 shares to 800,000,000 shares (the “Charter Amendment”).”
MANNKIND CORP shareholders approved Election of the nine nominees as directors at the 2023-05-25 meeting.
“Our stockholders elected each of the nine individuals nominated by the Board to serve as directors until the next annual meeting of stockholders.”
MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.
“1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022”
MANNKIND CORP reported the quarter ended March 31, 2023 results: revenue $41 million.
“(EX-99.1) --- EX-99 EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 • 1Q 2023 Revenues associated with Tyvaso DPI of $23 million • 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million • $167 million of Cash,”
Lauren M. Sabella was appointed as Executive Vice President, Chief Operating Officer at MANNKIND CORP.
“On March 21, 2023, Lauren M. Sabella was appointed by the board of directors of MannKind Corporation (the “Company”) as Executive Vice President, Chief Operating Officer of the Company, with such appointment to be effective on March 27, 2023.”
MANNKIND CORP reported the nine months ended September 30, 2022 results: revenue $63.7 million.
“Total revenues were $63.7 million for the nine months ended September 30, 2022”
MANNKIND CORP reported the third quarter ended September 30, 2022 results: revenue $32.8 million, net income $14.4 million, EPS $0.06 per share.
“--- mnkd-ex991_6.htm EXHIBIT 99.1 MANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m. (ET) • 3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 2021 • 3Q 2022 Royalties from Tyvaso DPI of $6.2 million • 3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE”
Joseph Kocinsky changed role as Chief Technology Officer at MANNKIND CORP.
“On October 26, 2022, MannKind Corporation (the “Company”) and Joseph Kocinsky, the Company’s Chief Technology Officer, discussed and agreed that Mr. Kocinsky’s duties and responsibilities will be reduced such that he will no longer function in the same position, effective October 31, 2022 (the “Effective Date”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.